Jeremy Duffield, M.D., Ph.D., FRCP

Jeremy Duffield, M.D., Ph.D., FRCP

Former Chief Scientific OfficeratPrime Medicine· In proxies 2022–2025

Pay in FY2025-30% from the year before · Prime Medicine stock +18.8% the same year

Jeremy Duffield, M.D., Ph.D., FRCP was paid $1.3M in FY2025 (Dec), down 30%. Prime Medicine stock rose 18.8% that year.

Pay$100 in the stock at the end of FY22 → $19
Pay is from the Summary Compensation Table of each Prime Medicine proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Prime MedicinePublic company · 4 yr
    • Former Chief Scientific Officer2022 – Present · 4 yrStock in role -65%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?